model systems, especially rodents, have hampered the assessment of the value of potential new drug targets (target qualification) and have led to calls for proof-of-concept human studies as the ultimate approach in hypothesis testing for target validation 5 . However, clinical proof-of concept validation studies are expensive and carry risk, and will always be limited in number. Other challenges arise from the lack of informative biomarkers to guide proof-of-concept clinical studies and clinical development (for example, by patient stratification), subjective clinical endpoints, and high placebo response rates (particularly in major depression) 6 .
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model systems, especially rodents, have hampered the assessment of the value of potential new drug targets (target qualification) and have led to calls for proof-of-concept human studies as the ultimate approach in hypothesis testing for target validation 5 . However, clinical proof-of concept validation studies are expensive and carry risk, and will always be limited in number. Other challenges arise from the lack of informative biomarkers to guide proof-of-concept clinical studies and clinical development (for example, by patient stratification), subjective clinical endpoints, and high placebo response rates (particularly in major depression) 6 .
What can genetic studies offer for drug discovery? Human genetic studies have made tremendous progress in identifying loci linked to human disorders. Outside of psychiatry, these include high-risk mutations in single genes that identify specific targets for manipulation 4 . These include PCSK9, individuals with 'knockout' mutations in which have lower LDL cholesterol without obvious deleterious effects, which has led to promising results in clinical trials 7 ; loss of function mutations in SLC30A8 (ref. 8) , which reduce the risk of type 2 diabetes; oritized their drug discovery and clinical trial efforts in psychiatry 3 . However, there are many (183) clinical trials underway or registered, showing there is still considerable investment in the field. Supplementary Table 1 provides details of current and recent trials in psychiatry, including the nine disorders studied in the PGC phase 3.
The challenges in developing therapeutics for psychiatric disorders result from the paucity of novel, valid targets. This results from etiological heterogeneity, the complex and polygenic nature of genetic risk and the definition of psychiatric disorders on the basis of the range and duration of symptoms (which are subjective, self-reported or observational). In addition, the complexity of the human brain means that large gaps exist in our knowledge of how brain-expressed biochemical pathways relate to identified brain circuits and neuronal networks. The few examples of etiology-relevant, higher order human behavioral functional domains and behavioral quantitative trait dimensions 4 limit the potential targets and measurable readouts that can be used in animal and human experimental medicine studies. While target identification based on genetics and biology looks increasingly feasible, concerns about the validity of existing
The state of drug discovery in psychiatry In psychiatry, conventional drug discovery is at an impasse 1 . In 2015, three (cariprazine, aripiprazole lauroxil, and brexpiprazole) out of 45 new drugs approved by FDA were related to psychiatry. The mechanisms of action of these drugs are not novel as their pharmacology primarily targets dopamine and serotonin receptors. There still remain unmet medical needs and societal costs for psychiatric disorders that necessitate novel therapeutics 2 . In disorders where partially effective treatments already exist, drug development has a higher investment risk because any new drug must exceed the clinical efficacy of existing treatments or show equivalent efficacy together with significant improvements in safety and tolerability, as well as competing for market share with established standards of care. This is particularly difficult where there is a lack of novel targets with adequate validation. This has resulted in higher drug discovery and development costs and longer than average cycle time in both clinical trial execution and regulatory agency review. Some companies have paused or depriTranslating genome-wide association findings into new therapeutics for psychiatry
The available data indicate that psychiatric disorders are highly polygenic, and we now expect hundreds or thousands of individual variants to be associated with each disorder. A promising strategy to deal with the small effect sizes and plethora of results is to adopt a pathway-and network-informed interpretation of GWAS hits. An analysis by Cao and Moult 27 found that while only a small fraction of known drug targets are in GWAS loci (12 of 353 drug targets for 81 diseases), known drug targets are enriched threefold in the nearest neighbor interactors (proteins that physically interact with a given protein) of genes in GWAS loci and are also enriched in second order interactors. This is supported by GWAS results in type 2 diabetes 28 that found that pathways targeted by anti-diabetes drugs are enriched in genes from GWAS and their direct protein interactors. This pool of GWAS hits, their interacting partners and networks provides a resource for the identification of drug targets and for drug repositioning.
How can genetic and genomic data be used in drug development pipelines? A critical issue in the field is how to use genetics information to drive drug discovery. As reviewed above, it often is not clear what genes are driving the association for GWAS significant loci. A potentially paradigmic example has recently emerged. C4 copy number was recently confirmed as a schizophrenia risk locus potentially affecting synaptic pruning in neurodevelopment; this study used PGC2 schizophrenia GWAS data, expression data from 700 postmortem brains, and genetic engineering of mice to confirm a potential mechanism 20 . This is already encouraging the development of new therapeutics because synaptic pruning occurs as the brain develops to full maturity in the late teens and early adulthood, providing time during which therapeutic interventions may be possible.
Relatively few GWAS hits have thus far been studied in such detail. However, much GWAS evidence converges on particular biological pathways, which are in themselves more druggable than single genes 29 . The pharmaceutical industry has also embarked on efforts to understand gene associations and the biological pathways impacted 5 . We need to link risk loci information to our understanding of pathways to help identify relevant biological processes, cell types and brain circuits and to home in on new molecular hypotheses and possible targets 30 . This need has sparked several academic projects and industry-academia precompetitive collaborations. There are many open-source and/or publically available efforts. These include large databases, rangthousands of independent genetic associations expected for each disorder 18 . This does not mean the whole genome will eventually be implicated; rather, we expect thousands of physically overlapping and independently associated loci to cluster onto hundreds of gene regions. The available evidence suggests these hits will converge onto both specific genes and biological pathways.
Insight into which genes (and which gene products) are implicated and the direction of effect is needed to determine the most appropriate therapeutic strategy. A general understanding of the additional analysis needed in the target identification and qualification process has developed: mapping from GWAS locus to gene to determine which gene(s) give rise to the association, plus functional studies of how the disease-associated SNPs operate (modality), either via regulatory effects (for example, affecting RNA splicing or levels) or through direct functional effects (affecting the nature and function of a protein). In this way, therapeutics targeting single GWAS identified targets, such as HMGCR in the LDL cholesterol metabolism responsible for hypercholesterolemia 19 , have been successfully developed. This process is beginning for schizophrenia 20 , and the PGC aims to accelerate this for all psychiatric disorders.
One problem is that GWAS hits identify variants, usually SNPs, that mark regions of the genome, so-called 'loci' , but in most cases do not directly identify the genes themselves nor their causal alleles. A GWAS locus often includes multiple genes within the region of statistical significance, and a hit within a gene does not guarantee that that is the gene involved; the functional effect of the variants is not usually obvious, and it may even have a regulatory effect on a gene outside the GWAS risk locus. Data from large-scale genomic and systems biology experiments are being used to identify expression, protein and methylation quantitative trait loci (eQTLs, pQTLs and mQTLs, respectively) to better map causal alleles 21, 22 . This includes imputation of gene expression profiles 23, 24 . A caveat is that linkage disequilibrium between markers often results in multiple genes in a region being implicated by expression imputation, recapitulating the initial problem. In addition, the lack as yet of large samples of available brain tissues from both patients and healthy donors at appropriate stages of development hampers the widescale application of this approach, although the CommonMind (see URLs) and BrainSeq 25 initiatives are taking strides in this direction (discussed below). It remains the case that each GWAS locus requires careful and custom examination (see Gandal et al. in this issue 26 ). and loss of function LPA mutations, which reduce plasma lipoprotein(a) levels and cardiovascular disease risk 9 .
With the notable exception of autism with intellectual disability, however, rare mutations account for a relatively small proportion of cases of disease in psychiatry, although this varies among disorders and their exact contribution is debated. Where they have been found, there is evidence that they converge on the same biological pathways as common variants: genes in schizophrenia GWAS-associated regions overlap those identified by sequencing studies focused on de novo damaging mutations in intellectual disability and autism [10] [11] [12] .
It may be more straightforward to identify a new target via rare mutations, but it is often not clear whether manipulating these targets will be effective in the wider disease population. The common disease-associated polymorphisms identified by GWAS in psychiatry and other complex disorders also have the potential to identify drug targets, as well as new etiologies that can kindle the generation of new model systems for therapeutic development in the wider population 13 . Several examples indicate that although GWAS loci have small effect sizes, they nonetheless may help identify targets for therapeutics, as shown in GWAS meta-analyses of lipid levels 14 , or existing drugs that can be repurposed for the treatment of diseases that they were not initially developed to treat, an approach known as drug repositioning 15, 16 . Integration of genetic data can be used for target selection, matching targets to indications while allowing a reduction in clinical trial costs; for example, by allowing more accurate identification of high-risk individuals. Targets with genetic support have been shown to have a higher chance of success 17 .
What is psychiatric genetics telling us?
The discovery of common genetic variants associated with risk for psychiatric illness has the capability of restarting hypothesis-led drug discovery. As for other complex genetic disorders, the application of human genetics to schizophrenia, led by the PGC (see URLs), has identified more and more disease susceptibility loci with increasing sample sizes. In 2014, the PGC identified over 100 robustly associated loci through case-control GWAS meta-analysis 10 . Similar progress is underway in other psychiatric disorders, with new successful GWAS reports expected for ADHD, autism, major depressive disorder, anorexia nervosa, and bipolar disorder in the next year.
The discovery of GWAS loci for these disorders is likely to continue for many years to come with, ultimately, many hundreds orCO M M E N TA RY coveries onto imaging, neurophysiological, and behavioral traits, to establish etiologically related intermediate phenotypes that could be useful in the development of novel therapeutics. These and many other efforts aimed at linking genetic variations associated with risk with circuitry and molecular targets are a needed next step.
Precision medicine for psychiatry and polygenic risk scores The customization of diagnosis and treatment to individuals is likely to have a role in clinical psychiatry. However, the extent to which this will be important and the proportions of individuals with a particular psychiatric disorder who might benefit from precision medicine is unclear and is now the subject of considerable research. Genomics is an important tool in the precision medicine toolbox. It is already important for several disorders and becoming common in clinical practice (for example, in the evaluation of children with intellectual disability and pervasive developmental delay). However, these studies are mostly focused on allow investigators to map genes identified in GWAS onto transcriptomics in post-mortem tissue from controls and cases with schizophrenia or bipolar disorder (as well as neuronal cell lines differentiated from induced pluripotent stem cells derived from cases and controls 31 ). A primary goal is to elucidate molecular mechanisms driven by risk variants, with the additional benefit that using genetic data can allow causal anchoring of molecular changes and pathology, thus avoiding incidental, downstream effects of the disorders themselves and their treatments 25 .
To advance our ability to understand GWAS data, the field will need to undertake further large-scale efforts to generate sufficient functional characterization of changes in brain gene and protein expression in patients and during development, and to move beyond schizophrenia and bipolar disorder to address many other disorders. The exploration and availability of large patient data sets is valuable. There are a number of initiatives in large, deeply phenotyped longitudinal samples aimed at mapping psychiatric genetic dising from ChEMBL, DGIdb and Drug Bank to K i DB from the Psychoactive Drug Screening Program (Table 1) , which serve as portals for identifying known molecular targets of drugs and drug-like small molecules. PHAROS (Table 1) is a new resource enabled by the NIH Druggable Genome Initiative (see URLs), which serves as a portal for a variety of useful information regarding druggable targets. Likewise Open Targets (formerly the Centre for Therapeutic Target Validation), a publicprivate initiative in the UK, integrates a large number of data sources into one searchable platform for single targets.
To enable the integration of functional genomic data from post-mortem brain samples from cases and controls, new technologies are needed that enable the accurate identification of cell-type-specific 'omics' profiles and individual-level neuronal circuitry. Key examples driving the generation of large relevant data sets are industry-academia partnerships including the BrainSeq 25 , CommonMind (see URLs), and PsychENCODE (see URLs) projects, which The databases listed collect drug-target or drug-gene interactions mainly from published studies and from other databases. Some of them provide various drug-target bioactivities (K i , IC50, etc.); others produce their own unique activity from experimental measures (pChEMBL, CARLSBAD activity, ChemProt activity) or only indicate whether or not there is a drug-gene interaction (for example, DGIdb) and, if so, the type of interaction. Databases providing a collection of bioactivities (such as ChEMBL) should be curated to obtain drug-target interaction pairs; dissimilar activities should be assessed for the same drug-target pair in various studies. Databases with their own unique activity measure may be considered to have a higher curation level. Most of the databases listed offer a large panel of interactions and are not focused on a particular set of targets, genes or drugs, with the notable exception of K i DB, which is rich in psychoactive drugs and also contains internally derived data. However, a bias toward some targets or genes might exist in all these databases, since drug affinity research in certain areas (notably cancer but also mental health thanks to efforts such as K i DB) is more prolific.
disorders 41, 42 , integrative pathway analysis including common and rare variants might increase power to detect statistically significant enriched pathways. Using these data sources, three broad strategies are possible (Fig. 1) . The first is pathway analysis using the genetic variants found to be associated with psychiatric disorders using gene sets (pathways) annotated for their drug associations or corresponding to sets of ligands in publically available resources such as ChEMBL and K i DB to test whether these gene sets together harbor a significant association signal using the PGC pathway analysis pipeline 43 . The second is using relevant gene expression profiles identified from case-control transcriptome data and examining their similarity to induced gene expression changes in cell lines, as identified by the NIH LINCS project (see URLs) or in studies of neuronal cells derived from induced pluripotent stem cells, to identify potential pathways and molecules that alter the expression and/or function of identified targets 44 . This strategy of 'connectivity mapping' allows identification of compounds with a similar or opposite effect on gene expression as our findings and can point to possible new treatment targets. Finally, we can layer onto these approaches traditional pathway annotations and ontologies (particularly gene ontology (GO) and REACTOME) and newer data sources that may be less biased and more complete 45 to allow us to develop a mechanistic understanding.
Conclusions
These approaches require substantial and integrated efforts, involving consortia such as the PGC, other academic groups, and industry in a precompetitive framework to drive forward target identification and qualification to the point where confidence will be high enough to begin a clinical validation process. Sharing of data and expertise will be essential. It will only be through collaborative work that the field will muster enough breadth of data and resources for this effort to fulfill its translational potential beyond polygenic risk score and prediction, with the identification of new biology and eventually clearing the blockages in psychiatric drug discovery. or treatment response-for example, in first episode psychosis 37 .
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PGC phase 3: target identification in psychiatric GWAS data
To fully exploit GWAS data for drug development, we need to complement the direct identification of single targets and their interactors and the use of polygenic risk scores with pathway-driven approaches, explicitly targeting sets of GWAS implicated regions and proteins together. In our view, this may be a powerful means to discover new drug indications or targets that gains power by exploiting the underlying polygenic nature of these disorders. This mirrors the observation that many successful psychiatric (and other) drugs have complex receptor pharmacology profiles, binding multiple targets with different affinities. The PGC is planning to exploit pathway analysis methods 38 that show better control for type 1 error alongside chemoinformatically generated gene sets to identify drugs or molecules with sets of targets significantly enriched for association in GWAS data. Applying drug pathway analyses to psychiatric GWAS results will allow us to derive hypotheses about drug mechanisms of action and rational drug repurposing 39 . Rare variants, discovered by large-scale sequencing efforts, can also be included in these analyses, particularly the known recurrent copy number variations in autism and schizophrenia 40 . These are complemented by ongoing largescale sequencing efforts in these disorders. Although rare mutations are only found in a small percentage of cases of most common rare genetic variants of uncommonly large effect. For most individuals with serious psychiatric disorders, whose risk is mediated by the cumulative effect of large numbers of common genetic variant with or without important environmental impacts, it is not yet clear whether genomics will be an important part of precision medicine in psychiatry. We know that these genetic effects significantly affect risk 10, 29 , but the effects are not deterministic.
A key approach is to use polygenic risk scores (extensively reviewed and discussed elsewhere 32 ). A polygenic risk score (PRS) 33 is an approximate measure of an individual's common variant genetic propensity for a given disorder and, at a population level, shows some predictive power 34 for case-control status. PRS approaches provide several potential routes to drug development, including identification of genetically associated endophenotypes and biomarkers. PRS can also be exploited to improve clinical trial efficacy. So-called super controls can be chosen by selecting participants with very low PRS for the disease, or PRS for low risk of side effects or where differential diagnosis is unclear. This may convey particular benefit in trials for diseases such as Alzheimer's (being investigated by a new workgroup in the PGC), where defining cases and controls is challenging. Furthermore, prevention trials could enlist high-risk individuals from the top end of the PRS distribution 35 , which, among other benefits, may be less expensive and confounded than the sibling design 36 . Current studies in psychiatry are attempting to improve prediction of diagnosis GWAS data from multiple psychiatric disorders including >1 million samples Drug and small molecule target lists and annotation from multiple sources, e.g., ChEMBL and Ki DB
Drug target discovery
Use of robust statistical genetic methods to assess evidence and identify (1) potential single targets (2) molecules with 'drug pathway' association Biological pathway annotation e.g., GO, REACTOME Brain systems biology information from multiple sources, e.g., CommonMind, BrainSeq Figure 1 PGC GWAS drug target analysis strategy: utilizing diverse information sources for drug target discovery. Our goal will be to merge chemoinformatic databases with systems biology data such as large-scale brain-tissue gene expression analyses and established ontology or pathway databases. We will then apply robust statistical genetic approaches to assess the significance of pathway, drug or molecule enrichment in the GWAS data.
